Paroxysmal nocturnal hemoglobinuria is a clonal, hematopoietic stem cell disorder that manifests with hemolytic anemia and bone marrow failure. Eculizumab has been shown to improve anemia, decrease intravascular hemolysis and reduce the risk of thrombosis.
DESIGN AND METHODS:
This is a retrospective, single-center study of patients treated with Eculizumab and categorized according to response criteria. Complete response was defined as transfusion independence with normal hemoglobin for age/sex, absence of symptoms, and lactate dehydrogenase < 1.5 times the upper limit of normal. A good partial response was defined as decreased transfusions from pretreatment and lactate dehydrogenase <1.5 upper limit of normal without thrombosis. These patients did not achieve normal hemoglobins for age and sex. A suboptimal response was defined as unchanged transfusion needs and persistent of symptoms.
Thirty patients with PNH clones were treated with eculizumab and classified as complete responders (4 patients), good partial responders (16) and suboptimal responders (10) over 863 patient-months of treatment. Complete responders had a decrease in red cell clone size while good partial responders had an increase. Thirteen patients treated did not meet inclusion criteria for the clinical trials of eculizumab due to lack of transfusions or thrombocytopenia; eight had at least a good partial response.
Eculizumab is efficacious in patients with paroxysmal nocturnal hemoglobinuria, but responses can vary and may depend on underlying marrow failure, underlying inflammatory conditions and red cell clone size following treatment. Normalization of hemoglobin with decrease in red cell clone size may predict complete response
- paroxysmal nocturnal hemoglobinuria (PNH)